Orgenesis Inc . (NASDAQ: NASDAQ:ORGS), a biotech company specializing in cell and gene therapies, has announced a strategic partnership with London-based Harley Street Healthcare Group (HSHG). This collaboration aims to fast-track the development and commercialization of advanced wellness and longevity therapies worldwide.
The joint venture (JV), in which Orgenesis will hold a 49% stake and HSHG will own 51%, is set to focus on health and wellness services that include personalized care and regenerative therapies. The partnership's "Health-Wellness-as-a-Service" (HWAAS) model will utilize HSHG's healthcare network and Orgenesis' biotech innovations.
By 2024 end, the JV plans to launch a suite of products and services, including immune cell banking, longevity therapies, preventative illness screening, and stem cell-based regenerative treatments. The initial launch will target key global regions such as the United Kingdom, UAE, MENA, Canada, ASEAN, the Balkans, Africa, Latam, and the Indian subcontinent.
As part of the agreement, HSHG has committed to invest up to $10 million over the next three years into both Orgenesis and the JV. Vered Caplan, CEO of Orgenesis, expressed enthusiasm for the partnership's potential to redefine patient care and longevity through innovative health solutions.
Sanjeev Kumar, Founder & Chief Visionary Officer of HSHG, also commented on the shared vision of enhancing health outcomes and the pursuit of making "90 the new 50" through this venture.
This partnership marks a significant development for Orgenesis in its strategy to expand in the global wellness market, combining its expertise in cell and gene therapies with HSHG's clinical excellence.
The venture will develop and commercialize services such as personalized preventative care and regenerative therapies. Orgenesis will own 49% of the joint venture initially, with Harley Street Healthcare Group investing $5 million in Orgenesis common stock by the end of December 2024.
Orgenesis recently expanded its equity incentive plan by 9 million shares, aiming to attract and incentivize talent. This move followed the departure of three board members and the election of five new directors, each set to serve a one-year term.
Furthermore, Orgenesis has entered into a strategic collaboration with Germfree to make cell and gene therapy treatments more affordable and accessible. The partnership is expected to foster innovation, particularly in digital workflows and advanced quality management systems.
InvestingPro Insights
Orgenesis Inc. (NASDAQ: ORGS) has taken a bold step toward expanding its reach in the global wellness market through its strategic partnership with Harley Street Healthcare Group. With ambitions to redefine patient care and longevity, the company's financial health and market performance provide a backdrop for understanding its potential to execute on these plans.
InvestingPro data highlights a significant return over the last six months, with a 163.05% increase, suggesting strong investor confidence in Orgenesis's future prospects. Additionally, the company has experienced a noteworthy one-week price total return of 26.64%, reflecting recent positive market reactions. Despite these impressive returns, it is important to note that Orgenesis has a market capitalization of $42.09 million, which places it in the smaller spectrum of publicly traded companies, potentially subjecting it to higher volatility.
Two InvestingPro Tips that stand out for Orgenesis include a high shareholder yield and expectations for net income growth this year. These insights are particularly relevant as they suggest that investors may see a good return on their investments and that the company is on a trajectory for improved financial performance, possibly supported by its new venture into health and wellness services.
For readers looking to delve deeper into Orgenesis's financials and market potential, InvestingPro offers additional tips and metrics. Currently, there are 13 more InvestingPro Tips available for Orgenesis, providing a more comprehensive analysis for investors. These tips can be accessed through InvestingPro's platform, which offers detailed company insights for informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.